Vaxart Inc.
Vaxart Biosciences, Inc. was originally incorporated in California under the name West Coast Biologicals, Inc. in March 2004 and changed its name to Vaxart, Inc. ( Private Vaxart ) in July 2007, when it reincorporated in the state of Delaware. On February 13, 2018, Private Vaxart completed a reverse merger (the Merger ) with Aviragen Therapeutics, Inc. ( Aviragen ), pursuant to which P…
$0.44
-$0.02 (-3.26%)
EOD Oct 16, 2026
Operating margin is thin at 7.62%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 726.7% YoY with margins expanding 238.6pp.
Even for strong businesses, today's 3x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
2.6x earnings, 3.2x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$243M
▲ +726.7% YoY
Net Income (TTM)
$39M
▲ +124.4% YoY
Op. Margin
16.30%
▲ +238.6pp YoY
ROIC
47.33%
▲ +88.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$34M
▲ +116.7% YoY
Op. Cash Flow (TTM)
$34M
▲ +117.2% YoY
Net Debt
-$56M
Net Cash Position
Cash & Equiv.
$64M
5Y CAGR: +125.8%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Vaxart (VXRT) overvalued?
At a P/E of 2.6 and a price-to-free-cash-flow of 3.2, Vaxart (VXRT) trades below a two-stage DCF intrinsic value of about $7.21 per share, so at $0.44 the stock looks undervalued (1,520.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vaxart scores 84/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Vaxart's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $7.21 per share for VXRT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $5.41. At today's $0.44, that puts the stock about 1,520.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Vaxart a high-quality business?+
Vaxart scores 84 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 16.3% operating margin and a 47.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Vaxart a good stock to buy right now?+
That depends on valuation and quality together, not either alone. VXRT currently trades below its estimated intrinsic value and scores 84/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Biological Products, (No Diagnostic Substances)
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.